HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

New Horizon Health (6606 HK) - Behind the Trading Suspension and the Outlook

China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait

CPMC Holdings (906.HK) - ORG Can't Afford to Lose, But Baosteel Is a Step Ahead

Asia Cement China (743.HK) Privatization- There May Be "Surprises" Despite Disappointing Offer Price

Asia Cement (743 HK): $3.22/Share Offer - Really?

Event-Driven

<ul>
<li>Many minority shareholders have lodged complaints against ACC with the SFC, since unfair privatization price damages the ecology of the entire market.It depends on whether the SFC will take action.</li>
<li>The failure of privatization does not necessarily mean better returns for investors. On the contrary, it may result in greater losses. ACC can have other ways “hollow out” the Company.</li>
<li>Arbitrageurs can choose to bet on a second privatization (with higher Offer Price) and also on the potential dividends, but the prerequisite is that the management choose to "act honorably".</li>
</ul>


Many minority shareholders have lodged complaints against ACC with the SFC, since unfair privatization price damages the ecology of the entire market.It depends on whether the SFC will take action.
The failure of privatization does not necessarily mean better returns for investors. On the contrary, it may result in greater losses. ACC can have other ways “hollow out” the Company.
Arbitrageurs can choose to bet on a second privatization (with higher Offer Price) and also on the potential dividends, but the prerequisite is that the management choose to "act honorably".


Asia Cement China (743.HK) - Investors Are Facing the Dilemma of Low-Priced Privatization

Asia Cement (China)

Asia Cement China (743.HK) - Investors Are Facing the Dilemma of Low-Priced Privatization